CSHL Cancer Center Support Grant
CSHL Cancer Center Support Grant
批准号:
9975703
负责人:
David A Tuveson
金额:
$440.4万
依托单位国家:
美国
项目类别:
财政年份:
1997
资助国家:
美国
项目状态:
已结题
起止时间:
1997-08-01 至 2021-07-31
关键词:
AddressAnimal ModelBasic ScienceCancer BiologyCancer CenterCancer Center Support GrantCancer DiagnosticsCancer PatientCell Proliferation RegulationClinicClinicalCollaborationsCommunicationDevelopmentDiagnosisDiagnosticElementsEnvironmentFinancial SupportFoundationsFundingGene Expression RegulationGenomic approachGoalsHumanLaboratoriesMalignant NeoplasmsMissionMolecularNCI Center for Cancer ResearchNational Cancer InstituteOncogenesProductivityPublic HealthResearchResearch PersonnelResource SharingResourcesScienceScientistServicesSignal TransductionTechnologyTherapeuticTranslatingTranslational ResearchTreatment Efficacyanticancer researchcancer diagnosiscancer geneticscancer subtypescancer therapyclinical applicationcollaborative approachdesigngenetic approachhigh throughput screeningimprovedinnovationinsightmembermultidisciplinarynew therapeutic targetnovel diagnosticsnovel therapeuticspre-clinicalprogramsresistance mechanismsingle cell sequencingtherapeutic effectivenesstherapeutic targettooltumor
中文摘要
CSHL癌症中心-整体项目摘要/摘要
冷泉港实验室(CSHL)癌症中心是一个首屈一指的癌症研究中心,
创新和合作的方法来解决癌症面临的一些最紧迫的挑战
生物学家和癌症患者。特别是,CSHL癌症中心的研究主要集中在两个主要方面,
问题:改善癌症诊断和提高治疗效果。
CSHL癌症中心的研究人员正在采用最先进的遗传和基因组方法,
从分子上表征癌症。这项研究的目标是开发新的诊断工具,
还定义癌症亚型,以便临床医生能够选择最有效的治疗方法。
CSHL癌症中心的研究人员处于开发和应用这些基因组方法的最前沿;
像单细胞测序这样的发现有能力彻底改变诊断方法,
在临床上显示出巨大的潜力。
CSHL癌症中心是建立在其基础发现科学的杰出基础上,
为多种肿瘤类型开发新的治疗靶点。十多年前,癌症中心
通过创建“癌症发现管道”将这一战略正式化。该计划将基本癌症
生物学、人类癌症遗传学、高通量筛选技术和创新的动物模型,
努力改善现有的癌症治疗方法。这条管道非常成功。癌
中心研究人员发现了新的癌症基因,确定了潜在的治疗靶点,并探索了
新的耐药机制。随着这项基础研究的继续,癌症中心的目标是扩大
管道甚至进一步转化研究。在接下来的五年里,作为癌症治疗的一部分,
倡议,癌症中心将把其基础研究发现,临床前和临床设置。
来自国家癌症研究所的资金为CSHL癌症中心提供了组织和
需要财政支持,以便对癌症诊断和治疗产生重大影响。三项研究
项目(基因调控和细胞增殖;信号转导;癌症遗传学)提供了机会
让成员聚在一起,最大限度地提高协作和沟通。9共享资源
提供技术、服务和专业知识,以提高生产力,促进多学科
交互.基本发展基金使该中心能够保持在癌症研究的最前沿。
总之,CSHL癌症中心的这些元素创造了一个支持癌症水平的环境。
在改善癌症诊断和治疗方面取得真实的进展所需要的科学发现。
英文摘要
CSHL Cancer Center – Overall Project Summary/Abstract
The Cold Spring Harbor Laboratory (CSHL) Cancer Center is a premier cancer research center that uses
innovative and collaborative approaches to address some of the most pressing challenges facing cancer
biologists and cancer patients today. In particular, research in CSHL Cancer Center is focused on two primary
problems: improving cancer diagnostics and increasing therapeutic effectiveness.
Researchers in the CSHL Cancer Center are employing cutting edge genetic and genomic approaches to
molecularly characterize cancer. The goals of this research are to both develop new diagnostic tools and to
also define cancer subtypes so that clinicians will be able to select the most effective therapeutic approaches.
CSHL Cancer Center researchers are at the forefront of developing and applying these genomic approaches;
discoveries like single cell sequencing have the power to revolutionize diagnostics and are already
demonstrating tremendous potential in the clinic.
The CSHL Cancer Center is building upon its outstanding foundation in basic discovery science to identify and
develop new therapeutic targets for multiple tumor types. More than ten years ago, the Cancer Center
formalized this strategy with the creation of a “cancer discovery pipeline.” The plan integrated basic cancer
biology, human cancer genetics, high-throughput screening technology, and innovative animal models in an
effort to improve existing treatments for cancer. This pipeline has been tremendously successful. Cancer
Center researchers have discovered new cancer genes, identified potential therapeutic targets, and explored
new drug resistance mechanisms. As this basic research continues, the Cancer Center is aiming to extend the
pipeline even further into translational research. Over the next five years, as part of a Cancer Therapeutics
Initiative, the Cancer Center will bring its basic research discoveries to preclinical and clinical settings.
Funding from the National Cancer Institute provides the CSHL Cancer Center with the organizational and
financial support needed to make a significant impact on cancer diagnosis and treatment. The three research
programs (Gene Regulation & Cell Proliferation; Signal Transduction; Cancer Genetics) provide opportunities
for members to come together, maximizing collaboration and communication. The nine Shared Resources
provide access to technologies, services, and expertise to enhance productivity and promote multidisciplinary
interactions. Essential Developmental Funds enable the Center to remain at the forefront of cancer research.
Together, these elements of the CSHL Cancer Center create an environment that supports the level of
scientific discovery required to make real progress in improving cancer diagnosis and treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Fibroblast Heterogeneity in Pancreatic Cancer
-
批准号:10675741
-
项目类别:
-
资助金额:$78.02万
-
财政年份:2021
-
负责人:David A Tuveson
-
依托单位:
Fibroblast Heterogeneity in Pancreatic Cancer
-
批准号:10299050
-
项目类别:
-
资助金额:$81.89万
-
财政年份:2021
-
负责人:David A Tuveson
-
依托单位:
Fibroblast Heterogeneity in Pancreatic Cancer
-
批准号:10467049
-
项目类别:
-
资助金额:$78.0万
-
财政年份:2021
-
负责人:David A Tuveson
-
依托单位:
Nrf2 Regulation of Ductal Pancreatic Cancer Etiology and Treatment Response
-
批准号:10056198
-
项目类别:
-
资助金额:$61.57万
-
财政年份:2016
-
负责人:David A Tuveson
-
依托单位:
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
-
批准号:9122093
-
项目类别:
-
资助金额:$56.05万
-
财政年份:2014
-
负责人:David A Tuveson
-
依托单位:
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
-
批准号:9336271
-
项目类别:
-
资助金额:$55.27万
-
财政年份:2014
-
负责人:David A Tuveson
-
依托单位:
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
-
批准号:8792084
-
项目类别:
-
资助金额:$55.57万
-
财政年份:2014
-
负责人:David A Tuveson
-
依托单位:
(PQA-4) Organoid Omics To Detect And Defeat Ductal Pancreatic Cancer
-
批准号:8930940
-
项目类别:
-
资助金额:$55.57万
-
财政年份:2014
-
负责人:David A Tuveson
-
依托单位:
Mutant mouse models of exocrine pancreatic cancer
-
批准号:7498542
-
项目类别:
-
资助金额:$20.99万
-
财政年份:2004
-
负责人:David A Tuveson
-
依托单位:
Mutant mouse models of exocrine pancreatic cancer
-
批准号:6916463
-
项目类别:
-
资助金额:$30.65万
-
财政年份:2004
-
负责人:David A Tuveson
-
依托单位:
Mutant mouse models of exocrine pancreatic cancer
-
批准号:7227182
-
项目类别:
-
资助金额:$20.99万
-
财政年份:2004
-
负责人:David A Tuveson
-
依托单位:
Mutant mouse models of exocrine pancreatic cancer
-
批准号:6829313
-
项目类别:
-
资助金额:$31.91万
-
财政年份:2004
-
负责人:David A Tuveson
-
依托单位:
Mutant mouse models of exocrine pancreatic cancer
-
批准号:7084399
-
项目类别:
-
资助金额:$29.87万
-
财政年份:2004
-
负责人:David A Tuveson
-
依托单位:
CSHL Cancer Center Support Grant
-
批准号:9321024
-
项目类别:
-
资助金额:$439.54万
-
财政年份:1997
-
负责人:David A Tuveson
-
依托单位:
Administration
-
批准号:10675614
-
项目类别:
-
资助金额:$20.44万
-
财政年份:1997
-
负责人:David A Tuveson
-
依托单位:
Leadership, Planning and Evaluation
-
批准号:10270216
-
项目类别:
-
资助金额:$27.01万
-
财政年份:1997
-
负责人:David A Tuveson
-
依托单位:
Administration
-
批准号:10270209
-
项目类别:
-
资助金额:$20.44万
-
财政年份:1997
-
负责人:David A Tuveson
-
依托单位:
Developmental Funds
-
批准号:10675624
-
项目类别:
-
资助金额:$82.16万
-
财政年份:1997
-
负责人:David A Tuveson
-
依托单位:
CSHL Cancer Center Support Grant
-
批准号:10675613
-
项目类别:
-
资助金额:$449.55万
-
财政年份:1997
-
负责人:David A Tuveson
-
依托单位:
Leadership, Planning and Evaluation
-
批准号:10675627
-
项目类别:
-
资助金额:$27.01万
-
财政年份:1997
-
负责人:David A Tuveson
-
依托单位:
海外基金